Bendamustine rituximab (BR) versus ibrutinib (Ibr) as primary therapy for Waldenstrom macroglobulinemia (WM): An international collaborative study.

被引：0
|
作者：
Abeykoon, Jithma P.
Kumar, Shaji
Castillo, Jorge J.
D'Sa, Shirley
Kastritis, Efstathios
Durot, Eric
Uppal, Encarl
Morel, Pierre
Paludo, Jonas
Tawfiq, Reema
Sarosiek, Shayna
Ogunbiyi, M. Olabisi
Cornillet-Lefebvre, Pascale
Kyle, Robert A.
Delmer, Alain
Gertz, Morie A.
Dimopoulos, Meletios A.
Treon, Steven P.
Ansell, Stephen M.
Kapoor, Prashant
机构：
[1] Mayo Clin, Div Hematol, Rochester, MN USA
[2] Mayo Clin, Rochester, MN USA
[3] Harvard Med Sch, Dana Farber Canc Inst, Bing Ctr Waldenstroms Macroglobulinemia, Boston, MA USA
[4] Univ Coll London Hosp Fdn Trust, Ctr Waldenstroms Macroglobulinemia & Associated, London, England
[5] Natl & Kapodistrian Univ Athens, Dept Clin Therapeut, Athens, Greece
[6] CHU Reims, Hematol Clin, Reims, France
[7] Univ Coll London Hosp NHS Fdn Trust, London, England
[8] Ctr Hosp Schaffner, Lens, France
[9] Mayo Clin, Div Hematol, Rochester, MN USA
[10] Boston Univ, Med Ctr, Sect Hematol & Oncol, Boston, MA USA
[11] Univ Hosp Reims, Reims, France
[12] UFR Med, Reims, France
[13] Hop Robert Debr, Reims, France
[14] Gen Hosp Athens Alexandra, Therapeut Clin, Athens, Greece
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7566
引用
收藏
页数：1
相关论文
共 29 条
  • [1] Bendamustine rituximab primary therapy for Waldenstrom Macroglobulinemia: an international, multicenter collaborative study
    Zanwar, Saurabh
    Abeykoon, Jithma
    Castillo, Jorge
    Durot, Eric
    Kastritis, Efstathios
    Uppal, Encarl
    Morel, Pierre
    Tawfiq, Reema
    Montes, Lydia
    Paludo, Jonas
    Saroseik, Shayna
    Kumar, Shaji
    Ogunbiyi, Olabisi
    Cornillet-Lefebvre, Pascale
    Kyle, Robert
    Delmer, Alain
    Gertz, Morie
    Dimopoulos, Meletios A.
    Ansell, Stephen
    Treon, Steven
    D'Sa, Shirley
    Kapoor, Prashant
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S127 - S128
  • [2] Bendamustine and Rituximab Versus Dexamethasone, Rituximab and Cyclophosphamide in Patients with Waldenstrom Macroglobulinemia (WM)
    Paludo, Jonas
    Abeykoon, Jithma P.
    Hesse, Amber B.
    Shreders, Amanda
    Ailawadhi, Sikander
    Ansell, Stephen
    Gertz, Morie A.
    Reeder, Craig B.
    King, Rebecca L.
    Kyle, Robert A.
    Buadi, Francis K.
    Dispenzieri, Angela
    Lacy, Martha Q.
    Habermann, Thomas M.
    Dingli, David
    Witzig, Thomas E.
    Go, Ronald S.
    Gonsalves, Wilson I.
    Leung, Nelson
    Lin, Yi
    Lust, John A.
    Rajkumar, S. Vincent
    Kumar, Shaji
    Kapoor, Prashant
    BLOOD, 2016, 128 (22)
  • [3] Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenstrom macroglobulinemia
    Paludo, Jonas
    Abeykoon, Jithma P.
    Shreders, Amanda
    Ansell, Stephen M.
    Kumar, Shaji
    Ailawadhi, Sikander
    King, Rebecca L.
    Koehler, Amber B.
    Reeder, Craig B.
    Buadi, Francis K.
    Dispenzieri, Angela
    Lacy, Martha Q.
    Dingli, David
    Witzig, Thomas E.
    Go, Ronald S.
    Gonsalves, Wilson I.
    Kourelis, Taxiarchis
    Warsame, Rahma
    Leung, Nelson
    Habermann, Thomas M.
    Hayman, Suzanne
    Lin, Yi
    Kyle, Robert A.
    Rajkumar, S. Vincent
    Gertz, Morie A.
    Kapoor, Prashant
    ANNALS OF HEMATOLOGY, 2018, 97 (08) : 1417 - 1425
  • [4] Ibrutinib/rituximab versus placebo/rituximab in Waldenstrom's Macroglobulinemia (WM): results of a randomized phase 3 trial
    Buske, C.
    Tedeschi, A.
    Trotman, J.
    Garcia-Sanz, R.
    MacDonald, D.
    Leblond, V
    Mahe, B.
    Herbaux, C.
    Tam, C. S.
    Palomba, M. L.
    Matous, J., V
    Shustik, C.
    Kastritis, E.
    Treon, S. P.
    Li, J.
    Salman, Z.
    Graef, T.
    Dimopoulos, M. A.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 252 - 252
  • [5] Outcomes with rituximab plus bendamustine (R-Benda), dexamethasone, rituximab, cyclophosphamide (DRC), and bortezomib, dexamethasone, rituximab (BDR) as primary therapy in patients with Waldenstrom macroglobulinemia (WM).
    Abeykoon, Jithma P.
    Zanwar, Saurabh
    Ansell, Stephen M.
    Kumar, Shaji
    Thompson, Carrie A.
    Habermann, Thomas Matthew
    Witzig, Thomas E.
    Buadi, Francis
    Go, Ronald S.
    Gonsalves, Wilson I.
    Leung, Nelson
    Dispenzieri, Angela
    Kourelis, Taxiarchis
    Lacy, Martha
    Warsame, Rahma M.
    Inwards, David James
    Rajkumar, S. Vincent
    Kyle, Robert A.
    Gertz, Morie A.
    Kapoor, Prashant
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [6] Rituximab-based maintenance therapy in Waldenstrom macroglobulinemia: A case control study.
    Zanwar, Saurabh
    Abeykoon, Jithma P.
    Gertz, Morie A.
    Kumar, Shaji
    Inwards, David James
    Porrata, Luis F.
    Thompson, Carrie A.
    Witzig, Thomas E.
    Habermann, Thomas Matthew
    Go, Ronald S.
    Lacy, Martha
    Rajkumar, S. Vincent
    Dispenzieri, Angela
    Buadi, Francis
    Gonsalves, Wilson I.
    Leung, Nelson
    Hayman, Suzanne R.
    Kyle, Robert A.
    Ansell, Stephen M.
    Kapoor, Prashant
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [7] The initial "Flare" of IgM level after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia (WM): An eastern cooperative oncology group (ECOG) study.
    Ghobrial, IM
    Fonseca, R
    Greipp, PR
    Blood, E
    Rue, M
    Vesole, D
    Gertz, M
    BLOOD, 2003, 102 (11) : 448A - 449A
  • [8] ASPEN: Long-term follow-up results of a phase 3 randomized trial of zanubrutinib (ZANU) versus ibrutinib (IBR) in patients with Waldenstrom macroglobulinemia (WM).
    不详
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [9] Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenstrom's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study
    Buske, Christian
    Tedeschi, Alessandra
    Trotman, Judith
    Garcia-Sanz, Ramon
    MacDonald, David
    Leblond, Veronique
    Mahe, Beatrice
    Herbaux, Charles
    Matous, Jeffrey V.
    Tam, Constantine S.
    Heffner, Leonard T.
    Varettoni, Marzia
    Palomba, M. Lia
    Shustik, Chaim
    Kastritis, Efstathios
    Treon, Steven P.
    Ping, Jerry
    Hauns, Bernhard
    Arango-Hisijara, Israel
    Dimopoulos, Meletios A.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (01) : 52 - +
  • [10] Primary Therapy of Waldenstrom's Macroglobulinemia (WM) with Weekly Bortezomib, Low-Dose Dexamethasone and Rituximab (BDR): A phase II Study of the European Myeloma Network
    Dimopoulos, Meletios A.
    Garcia-Sanz, Ramon
    Gavriatopoulou, Maria
    Morel, Pierre
    Kyrtsonis, Marie-Christine
    Katodritou, Eirini
    Michalis, Eurydiki
    Kartasis, Zafiris
    Leleu, Xavier
    Palladini, Giovanni
    Tedeschi, Alessandra
    Gika, Dimitra
    Terpos, Evangelos
    Merlini, Giampaolo
    Kastritis, Efstathios
    Sonneveld, Pieter
    BLOOD, 2010, 116 (21) : 808 - 809
123